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ABSTRACT
A 78 year old male was hospitalized in neurology clinic with a diagnosis of encephalopathy. On 13th day of imipenem 
treatment for ventilator-associated pneumonia (VAP), a new VAP episode was diagnosed based on physical examina-
tion, laboratory and radiological findings. Cefoperazone-sulbactam 2x2 gr/day IV was started empirically. In the 3rd day 
of treatment Acinetobacter baumannii was identified from endotracheal aspirate culture that was resistant to all other 
antibiotics including colistin except cefoperazone-sulbactam (intermediate) and tigecycline (MIC: 4 mg/L, intermediate) 
by VITEK and E-test. Tigecycline 2 x 50 mg (after loading dose of 100 mg) IV, colistin IV 2 x 150 mg and colistin inhaler 2 
x 75 mg were added to the cefoperazone-sulbactam 2 x 2 gr IV. Clinical findings were improved under this combination 
and completed to 14 days. The patient was discharged from hospital with neurological sequel after three months. This 
case has been presented to emphasize that colistin resistant Acinetobacter baumannii is becoming a problem for our 
country. J Microbiol Infect Dis 2014; 4(3): 111-113
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Kolistin dirençli Acinetobacter baumannii’ye bağlı sağlık bakımı ile ilişkili bir pnömoni vakası
ÖZET
Yetmiş sekiz yaşındaki erkek hasta ensefalopati tanısı ile nöroloji bölümüne yatırıldı. Ventilatör ilişkili pnömoni (VİP) 
nedeniyle başlanan imipenem tedavisinin 13. gününde fizik muayene, laboratuar ve radyolojik bulgulara dayanarak 
yeni bir VİP tanısı kondu. Ampirik olarak sefoperazon sulbaktam 2 x 2 gr/gün IV tedavisi başlandı. Tedavinin 3. gününde 
endotrakeal aspirat kültüründe hem Vitek hem de e-testle sefoperazon-sulbaktam (orta duyarlı) ve tigesiklin (MIC: 4 
mg/L, orta duyarlı) hariç diğer tüm antibiyotiklere (kolistin dahil) dirençli Acinetobacter baumannii üremesi oldu. Sefo-
perazon-sulbaktam 2 x 2 gr/gün IV tedavisine tigesiklin 2 x 50 mg/gün (100 mg yükleme dozunu takiben) IV, kolistin 2 x 
150 mg/gün IV ve kolistin 2 x 75 mg/gün inhaler eklendi. Bu kombinasyon tedavisi altında hastada klinik yanıt alındı ve 
tedavi 14 güne tamamlandı. Hasta 3 ay sonra nörolojik sekel ile hastaneden taburcu edildi. Bu olgu kolistin dirençli Aci-
netobacter baumannii olgularının ülkemiz için bir sorun haline gelmeye başladığını göstermek amacıyla sunulmaktadır
Anahtar kelimeler: Acinetobacter baumannii, kolistin direnci, pnömoni, çoklu ilaç direnci
INTRODUCTION
Resistance to all major classes of antibiotics (except 
polymyxins) in Acinetobacter baumannii has sub-
stantially increased worldwide in the past decade. 
A. baumannii is now regarded as one of the most 
difficult nosocomial pathogens to treat and control.1 
In many cases, the available therapeutic options for 
MDR A. baumannii infection include colistin (poly-
myxin E) or polymyxin B. A relationship between the 
increasing rate of colistin usage and colistin resis-
tance in A. baumannii has been reported.2 Herein, 
a case of healthcare-associated pneumonia due to 
colistin resistant A. baumannii is presented.
CASE REPORT
A 78 year-old male was hospitalized in the neurol-
ogy clinic with a diagnosis of encephalopathy. The 
patient was transferred to the Intensive Care Unit Keske S, et al. Colistin resistant Acinetobacter baumannii 112
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(ICU) because of cardiopulmonary arrest on the 
18th day of hospitalization. Colistimethate sodium 
(Colimycin, Kocak Farma, Turkey) intravenous (IV) 
2 x 150 mg was administered empirically for three 
days with a diagnosis of ventilator-associated pneu-
monia (VAP). Colistin treatment was switched to imi-
penem after isolation of Enterobacter cloacae (106 
colony forming unit/mL) in an endotracheal aspirate 
fluid. On the 13th day of imipenem treatment, fever 
of 38.4°C with increased purulent respiratory secre-
tion was detected. On the physical examination, bi-
lateral rales were auscultated. The laboratory find-
ings revealed that white blood cells (WBC) 12.8 K/
µL, hemoglobin 8.6 g/dL, hematocrite 25.2%, plate-
let count 241 K/µL, sedimentation rate 82 mm/h, 
and C-reactive protein (CRP) 134 mg/L. Postero-
anterior lung radiography revealed a pulmonary in-
filtration on the right lung. After obtaining endotra-
cheal aspirate culture, imipenem was stopped, and 
cefoperazone-sulbactam 2 x 2 g/day was started 
empirically. On the 3rd day of treatment, A. bauman-
nii (≥105 colony forming unit/mL) was identified in 
the endotracheal aspirate fluid culture. The isolate 
was resistant to all of the antibiotics, including co-
listin, except for cefoperazone-sulbactam (interme-
diate) and tigecycline (MIC=4 mg/L, intermediate) 
by VITEK and E-test. Colistin resistance was con-
firmed twice with E-test. Colistimethate sodium IV 
2 x 150 mg plus colistimethate sodium inhaler 2 x 
75 mg were added to the cefoperazone-sulbactam 
2 x 2 g IV. On the 3rd day of this treatment, there 
was no growth from repeated endotracheal aspi-
rate culture, but his fever persisted and no clinical 
or laboratory response was achieved. Tigecycline 
was added to the therapy as 2 x 50 mg IV (after 
1 x 100 mg IV loading dose), although tigecycline 
was not approved for pneumonia. On the 6th day 
of cefoperazone-sulbactam, 4th day of colistin and 
2nd day of tigecycline, the patient’s clinical findings 
were improved, WBC decreased to normal range, 
and CRP levels declined. Antimicrobial therapy was 
stopped on the 14th day of colistin. The patient was 
discharged from the hospital with neurological se-
quelae after three months.
DISCUSSION
A substantial increase in MDR in A. baumannii has 
forced clinicians to use colistin alone or in combi-
nation with some other antibiotics.3 Tigecycline is a 
therapeutic option; however, besides the potential 
for toxicity. On the other hand, a high percentage 
(78%) of resistance to tigecycline among MDR A. 
baumannii isolates has been reported from Israel 
despite tigecycline has never been used.4 Several 
combinations with carbapenems, beta-lactam, dox-
ycycline, rifampicin, or azithromycin have been in-
vestigated for treatment of A. baumannii infections.5 
In a study by Kalin et al.6, clinical cure rates and 
bacteriological clearance rates were reported to be 
better in the colistin/sulbactam combination group 
than in colistin monotherapy, but the difference did 
not reach statistical significance.
Colistin resistance among Acinetobacter 
strains, especially in A. baumannii, is increasing. In 
different parts of the world, colistin-resistant Acineto-
bacter strains have been identified.7 In the literature, 
the most common risk factor was reported as previ-
ous colistin usage. In our case, colistin was used 
for three days with a diagnosis of VAP two weeks 
before colistin-resistant Acinetobacter growth in the 
endotracheal aspirate culture. This might have led 
to the colistin resistance. 
The pathogenesis of the emerging resistance 
in Acinetobacter is not well identified. Mutations in 
two genes that constitute a two-component system 
(PmrAB) involved in the modification of lipid A, the 
major constituent of the LPS membrane, and muta-
tions, deletions, or insertions in genes essential for 
the synthesis of lipid A were suggested as the pos-
sible mechanisms.8 
Synergism was demonstrated between colis-
tin and sulbactam, imipenem and rifampicin.8,9 In a 
study by Mutlu Yılmaz et al.10, despite detection of 
in-vitro synergistic activity, which was proven by the 
efficacy on bacterial counts in the lung tissue, the 
authors could not find any statistically significant dif-
ference between colistin, tigecycline and combina-
tion treatments. However, we preferred to continue 
cefoperazone-sulbactam to obtain a synergistic ef-
fect. 
On the basis of our experience, a clinical re-
sponse was observed on average five days later, 
even for colistin-susceptible MDR Acinetobacter in-
fections (unpublished data). Thus, in this case, the 
clinical response might have been obtained due to 
the combined use of colistin and cefoperazone-sul-
bactam. However, it is thought that tigecycline might 
also have an additional effect on this response be-
cause of its synergistic effect with colistin, which 
was shown in a recent article.9 
In conclusion, taking advantage of this synergic 
effect seems to be the most reasonable approach 
in the treatment of patients infected with MDR A. 
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